Centinel Spine today claimed it won the 1st multi-level indication for an interbody fusion device in the cervical spine, saying the FDA OK’d its Stalif C and Stalif C-Ti devices for then procedures. “This is a valuable indication given the high incidence of multilevel degenerative disc disease in the cervical spine. We are excited to be the 1st company to receive […]
Centinel Spine LLC
Earnings Roundup: Amgen’s 2010 sales, earnings flat
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past few days:
Paradigm BioDevices wins British contract dispute
A British court handed Paradigm BioDevices Inc. a win in its contract dispute with Centinel Spine LLC subsidiary Surgicraft Ltd., ruling that Surgicraft must pony up a kill fee for terminating a deal with Paradigm in 2008.
Rockland, Mass.-based Paradigm sued Surgicraft in 2008, after the Redditch, England-based firm abruptly canceled Paradigm’s exclusive deal to distribute Surgicraft’s Stalif TT spinal fusion device. Centinel, which is owned by New York-based orthopedics hedge fund Viscogliosi Brothers LLC, acquired Surgicraft in 2008.